Plain-English translation of NCT04927897 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is studying how to better target radiation therapy for rectal cancer patients who still have cancer after initial chemotherapy and radiation treatment. Researchers will use detailed imaging and tissue analysis to map exactly where cancer cells have spread, which will help doctors design more precise radiation therapy in the future.
Current methods of planning radiation therapy for rectal cancer may not capture all the microscopic cancer cells that have spread. By carefully mapping tumor spread in patients who are having surgery, doctors hope to improve how they design and deliver this specialized radiation therapy to be more effective and safer.
You likely qualify if…
You likely don't qualify if…
You will undergo standard care for rectal cancer, including imaging scans and a procedure called flexible endoscopy. Before surgery, you'll also have two additional imaging procedures (ultrasound and a viewing tube) performed while you are under general anesthesia, if these aren't already part of your routine care. After your surgery, researchers will scan some of your removed tissue using specialized imaging to map where cancer cells spread—this helps them understand how to target radiation therapy better in future patients.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Netherlands
Sponsor
Maastricht Radiation Oncology
Collaborators
Maastricht University Medical Center, Catharina Ziekenhuis Eindhoven
Enrollment target
~50 participants
Started
August 2022
Primary completion
May 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Maaike Berbée, MD, PhD
Maastro
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.